AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases

Inclusion Criteria: * Pathologically confirmed non-small cell lung cancer; * clinical stage IV (AJCC, 8th edition, 2017); * EGFR sensitive mutations: EGFR L858R, EGFR exon 19 deletion; * age≥18 years old; * KPS score≥70; * brain metastases at diagnosis; * complete systemic imaging (including brain MRI) before third-generation EGFR-TKI treatment; * received standard third-generation EGFR-TKI therapy (monotherapy or combined with brain radiotherapy); * willing to cooperate with the follow-up after third-generation EGFR-TKI treatment; * informed consent of the patient. Exclusion Criteria: * Multiple primary or metastatic tumors (except early skin cancer, cervical carcinoma in situ that has been treated radically, with no recurrence or progression for more than 5 years); * Pregnant or lactating women who, as judged by the investigator, were not candidates for brain MRI; * EGFR sensitive mutations were negative or EGFR mutation status was not detected. * Uncontrolled epilepsy, central nervous system disease, or history of mental disorders, judged by the researcher to potentially interfere with the signing of the informed consent form or affect patient compliance.